A Multicenter Double-Blind Randomized Placebo-Controlled Parallel Group Study with Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects with Dravet Syndrome

Brief description of study

The purpose of this study is to assess the safety (symptoms and medical problems you may experience –known as side effects) and efficacy (how well and for how long the study drug works) of the study drug lorcaserin on subjects who have Dravet syndrome.Lorcaserin is an investigational drug that is manufactured by Eisai, a pharmaceutical company that is also the sponsor of this study. Some people with epilepsy who took lorcaserin for their seizures found it to be helpful. However, as lorcaserin has not been studied in Dravet syndrome, there is no guarantee that lorcaserin will improve your seizure control. This study will help us learn more about lorcaserin in people with Dravet syndrome.

Clinical Study Identifier: s20-01182
ClinicalTrials.gov Identifier: NCT04572243
Principal Investigator: Orrin Devinsky.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.